Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial.

@article{Ritsner2010PregnenoloneAD,
  title={Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial.},
  author={Michael S. Ritsner and Anatoly Gibel and Tatyana Shleifer and Igor Boguslavsky and Ahmad S. Zayed and Rachel Maayan and Abraham Weizman and Vladimir Lerner},
  journal={The Journal of clinical psychiatry},
  year={2010},
  volume={71 10},
  pages={1351-62}
}
OBJECTIVE Pregnenolone (PREG) and dehydroepiandrosterone (DHEA) are reported to have a modulatory effect on neuronal excitability, synaptic plasticity, and response to stress; they are associated with mood regulation and cognitive performance. We investigated the influence of PREG and DHEA on psychotic symptoms and cognitive functioning as an add-on to ongoing antipsychotic treatment of patients with chronic schizophrenia or schizoaffective disorder. METHOD This 8-week, double-blind… CONTINUE READING